论文部分内容阅读
为了建立一种稳定可靠的多药耐药基因（ＭＤＲ１）ｍＲＮＡ检测方法，探讨ＭＤＲ１基因表达检测的临床价值，我们采用ＲＴ－ＰＣＲ１方法定量检测了Ｋ５６２、Ｋ５６２／ＡＤＭ细胞株和３０例初治急性白血病ＭＤＲ１的表达水平。结果发现：１）耐药Ｋ５６２／ＡＤＭ１细胞系的ＭＤＲ１表达较高，而Ｋ５６２敏感细胞系无表达。２）初治急性白血病患者ＭＤＲ１阳性表达率４０．０％，表达值为０．２２０８±０．０８９６。３）５例正常人对照均无ＭＤＲ１阳性表达。４）初治急性白血病ＭＤＲ１阳性表达组缓解率为４１．７％，明显低于阴性组８８．９％（Ｐ＜０．０１）。我们认为ＲＴ－ＰＣＲ是一种敏感性高、特异性强、可定量检测ＭＤＲ１表达手段，有临床实用价值；另外，初治急性白血病患者ＭＤＲ１表达检测的结果表明，ＭＤＲ１表达增加是化疗的一个不利因素，且对化疗方案的选择有一定的指导意义。
To establish a stable and reliable multidrug resistance gene (MDR1) mRNA detection method and explore the clinical value of MDR1 gene expression detection, we used RT-PCR1 method to quantitatively detect K562, K562 / ADM cell lines and 30 newly diagnosed acute Leukemia MDR1 expression levels. The results showed that: 1) MDR1 expression was higher in K562 / ADM1 cell line than in K562 / ADM1 cell lines, but not in K562 cells. 2) MDR1 positive rate in newly diagnosed acute leukemia patients was 40.0%, the expression value was 0.2208 ± 0.0896.3) There was no MDR1 positive expression in 5 normal controls. 4) The remission rate of newly diagnosed acute leukemia MDR1 positive expression group was 41.7%, which was significantly lower than that of the negative group (88.9%, P <0.01). In our opinion, RT-PCR is a sensitive and specific method that can quantitatively detect MDR1 expression and has clinical value. In addition, MDR1 expression in newly diagnosed acute leukemia patients shows that MDR1 expression is an adverse effect of chemotherapy Factors, and the choice of chemotherapy regimen has some guiding significance.